The discovery of potent MRCK inhibitors has enabled the characterization of the role of these kinases in cytoskeleton regulation, morphology and motility [11,12], as well as in skin cancer growth and glioma invasion [11,13]. This evidence concerns the gene CDC42BPA and central nervous system cancer.